Safety Study of CTS21166 to Treat Alzheimer Disease

CoMentis

Status and phase: Completed; Phase 1

Conditions: Alzheimer's Disease

Treatments: Drug: CTS21166 (ZPQ-21166)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00621010

CTS21166-101

Details and patient eligibility

About

This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers

Enrollment: 56 patients

Sex: Male

Ages: 22+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adult male > age 21;
• non-smoker (minimum 6 months);

Exclusion criteria

• History or evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, psychiatric, oncologic, or allergic (including anaphylactic drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease
• History or evidence of intravenous illicit drug use, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C;
• Participation in another clinical trial within 30 days prior to dosing

Trial design

56 participants in 1 patient group

Cohort

Experimental group

Treatment:

Drug: CTS21166 (ZPQ-21166)